← GIP/GLP-1 & amylin agonists × cardiovascular events

Observational studyESC heart failure2026

Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.

Luca Monzo et al.PubMed ↗Full text ↗Publisher ↗

What moved togetherboth groups pooled, not the treatment’s effect

Correlation · may be no link

No clear link with cardiovascular events

+14%−11% to +46%

Bigger than 2 in 10 for cardiovascular events

As reported

HR 1.14, 95% CI 0.89–1.46

Correlation · may be no link

No clear link with cardiovascular events

1.2×0.6× to 2.4×

Bigger than 4 in 10 for cardiovascular events

As reported

HR 1.24, 95% CI 0.63–2.44

Correlation · may be no link

No clear link with cardiovascular events

+10%−15% to +43%

Bigger than 1 in 10 for cardiovascular events

As reported

HR 1.10, 95% CI 0.85–1.43

Three numbers in the abstract

the abstract, start to end

… of the primary composite endpoint (HR 1.14 [95% CI, 0.89-1.46]; P = .286), and of its individual components (all-cause death: HR 1.24 [95% CI, 0.63-2.44]; P = .531; HF hospitalization: HR 1.10 [95% CI, 0.85-1.43]; P = .471), …

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 1.140.89–1.46
Cardiovascular events
HR 1.240.63–2.44
Cardiovascular events
HR 1.100.85–1.43
GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsCardiovascular events
1 / 3

3 papers cite it

2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 41711744